Evidence map›Paper›PMID 39757193›Full record

SynthesisBMC cardiovascular disorders2025

Association between vascular endothelial growth factor and atrial fibrillation: a systematic review.

Nikhil Sharma, Mahalaqua Nazli Khatib, R Roopashree, Mandeep Kaur, Manish Srivastava, Amit Barwal, G V Siva Prasad, Pranchal Rajput, Rukshar Syed, Kamal Kundra and 11 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Pannexins in the vasculature.American journal of physiology. Heart and circulatory physiology · 2025
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nikhil Sharma *Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Guwahati, 781101, India.
Mahalaqua Nazli Khatib *Division of Evidence Synthesis, Global Consortium of Public Health and Research, Datta Meghe Institute of Higher Education, Wardha, India.
R RoopashreeDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Mandeep KaurDepartment of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, 303012, Rajasthan, India.
Manish SrivastavaDepartment of Endocrinology, NIMS University, Jaipur, India.
Amit BarwalChandigarh Pharmacy College, Chandigarh Group of College, Jhanjeri, Mohali, 140307, Punjab, India.
G V Siva PrasadDepartment of Chemistry, Raghu Engineering College, Visakhapatnam, 531162, Andhra Pradesh, India.
Pranchal RajputSchool of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, India.
Rukshar SyedIES Institute of Pharmacy, IES University, Bhopal, 462044, Madhya Pradesh, India.
Kamal KundraNew Delhi Institute of Management, Tughlakabad Institutional Area, New Delhi, India.
Vinamra MittalGraphic Era (Deemed to be University), Graphic Era Institute of Medical Sciences, Clement Town, Dehradun, India.
Muhammed ShabilNoida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, India. mohdshabil99@gmail.com.
Amit KumarCentre of Research Impact and Outcome, Chitkara University, Rajpura, 140417, Punjab, India.
Pancham CajlaChitkara Centre for Research and Development, Chitkara University, 174103, Chandigarh, Himachal Pradesh, India.
Ganesh BushiSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India.
Rachana MehtaClinical Microbiology, RDC, Manav Rachna International Institute of Research and Studies, 121004, Faridabad, Haryana, India.
Zaid KhanCenter for Global Health Research, Saveetha Institute of Medical and Technical Sciences, Saveetha Medical College and Hospital, Saveetha University, Chennai, India.
Prakasini SatapathyUniversity Center for Research and Development, Chandigarh University, Mohali, Punjab, India.
Shilpa GaidhaneOne Health Centre (COHERD), Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education, Wardha, India. shilpa.gaidhane@dmiher.edu.in.
Afukonyo Shidoiku DanielGlobal Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nigeria. afukonyoshidoiku@tsuniversity.edu.ng.
Renu SahSR Sanjeevani Hospital, 56517, Kalyanpur, Siraha, Nepal. renusahdoc@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtrial fibrillation (AF) is the most prevalent form of sustained cardiac arrhythmia, with vascular endothelial growth factor (VEGF) increasingly recognized for its potential role in the pathogenesis of AF through mechanisms involving atrial remodeling, inflammation, and fibrosis. This systematic review aims to synthesize available evidence on the association between VEGF and AF, exploring the implications of VEGF as a biomarker and therapeutic target.

methodsWe conducted a comprehensive search across PubMed, Embase, and Web of Science until November 10 2024, selecting studies based on pre-defined criteria that involve adults with AF and measurements of VEGF levels. The selected studies included observational and experimental designs, excluding non-English and methodologically insufficient publications. Narrative synthesis was used for summarising the results.

resultsEight studies met the inclusion criteria. The studies show a general trend of elevated VEGF levels in AF patients compared to controls, with significant heterogeneity in findings across studies. VEGF subtypes such as VEGF-A and VEGF-D demonstrated stronger associations with AF risk compared to VEGF-C. These variations point to the complex role of VEGF in AF, influencing factors like angiogenesis, endothelial function, and inflammatory responses.

conclusionVEGF is potentially a significant contributor to AF pathophysiology, with its levels reflecting disease activity. The variability observed across studies suggests a need for standardized measurement approaches and further investigation into VEGF subtypes. Future research should focus on longitudinal studies to better understand the causal relationships and the potential of VEGF as a therapeutic target and biomarker in AF management. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Atrial FibrillationBiomarkersVascular Endothelial Growth Factor AAgedFemaleHumansMaleMiddle AgedPrognosisRisk AssessmentUp-RegulationBiomarkersVascular Endothelial Growth Factor AVEGFA protein, humanAngiogenesisAtrial fibrillationBiomarkersCardiac arrhythmiaInflammationSystematic reviewVEGF

Identifiers

PMID39757193
PMCPMC11702055

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.